Full-Time

Scientist II

In-Vivo Pharmacology, Must have oncology experience

Posted on 7/10/2024

Scorpion Therapeutics

Scorpion Therapeutics

51-200 employees

Develops precision oncology treatments for cancer

Junior, Mid

Boston, MA, USA

Category
Lab & Research
Life Sciences
Required Skills
Communications
Requirements
  • PhD. in pharmacology, biology or a related field
  • 1+ years of industry experience in the oncology space required
  • Experienced with cell culture and molecular biology techniques such as western blotting, qPCR and other plate-based assays and imaging techniques
  • Skilled in animal handling, compound formulation, dosing (PO/IV/SC/IP), basic surgery and necropsy techniques
  • Outstanding organizational, analytical and interpersonal skills
  • Ability to multi-task in a fast-paced environment while maintaining the highest quality of experimental execution/quality
  • Desire to contribute to teams working on challenging technical and scientific problems
  • A strong record of achievement, including publications
Responsibilities
  • Plan and coordinate in vivo experiments in-house and externally
  • Leverage organizational and communication skills to collaborate effectively with colleagues in biology and medicinal chemistry
  • Represent pharmacology on multiple project core teams
  • Analyze and present data to project teams and department meetings
  • Maintain high-quality, detailed experimental records within the ELN
  • Design and execute PK/PD/efficacy studies
Scorpion Therapeutics

Scorpion Therapeutics

View

Scorpion Therapeutics develops precision oncology treatments aimed at targeting specific cancer drivers. Their approach involves creating drugs that interact with validated cancer targets, enhancing their selectivity and safety to improve treatment outcomes. Unlike many competitors, Scorpion Therapeutics focuses on forming partnerships with larger pharmaceutical companies for the distribution of their drugs, allowing them to concentrate on research and development. Their goal is to provide effective cancer therapies that can make a significant impact on patients' lives.

Company Size

51-200

Company Stage

Series C

Total Funding

$408.5M

Headquarters

Boston, Massachusetts

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $150M in Series C funding, strengthening their oncology pipeline and financial position.
  • Partnership with Pierre Fabre enhances distribution and sales capabilities in Europe and China.
  • Growing demand for CNS-penetrant therapies aligns with Scorpion's focus on innovative cancer treatments.

What critics are saying

  • Recent leadership changes may disrupt strategic direction and operational continuity.
  • Reliance on partnerships for revenue exposes Scorpion to financial risks if expectations aren't met.
  • Intensifying competition in precision oncology could impact Scorpion's market share and pricing power.

What makes Scorpion Therapeutics unique

  • Scorpion Therapeutics specializes in precision medicine for cancer, focusing on small-molecule drugs.
  • Their Precision Oncology 2.0 strategy aims to redefine cancer treatment with innovative approaches.
  • Scorpion's STX-478 and STX-721 show potential best-in-class profiles for specific cancer mutations.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

1%

2 year growth

6%
Pharmaceutical Technology
Jul 17th, 2024
Scorpion Therapeutics secures $150m for oncology pipeline

In conjunction with the funding, Lightspeed Venture partner Shelley Chu will become an investor board member and Frazier Life Sciences managing partner Albert Cha will join the board of Scorpion as an observer.

Finsmes
Jul 16th, 2024
Scorpion Therapeutics Raises $150M in Series C Financing

Scorpion Therapeutics, a Boston, MA-based clinical-stage oncology company, raised $150M in Series C funding

Fierce Biotech
Jan 4th, 2024
Scorpion's CEO Axel Hoos, CMO bite the dust as oncology biotech brings in new leadership

Streit joined Scorpion in 2022 from Sanofi, where he had most recently served as vice president and senior project head.

Business Wire
Jan 4th, 2024
Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team

Scorpion Therapeutics appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and expands Leadership Team.

Yahoo Finance
Oct 24th, 2023
Scorpion Therapeutics Appoints Precision Medicine Leader Jeff Albers as Strategic Advisor

Scorpion Therapeutics appoints precision medicine leader Jeff Albers as strategic advisor.

INACTIVE